RxDoctor Payments Data

Courtney Tyner, PA

Physician Assistant · Edmond, OKNPI 1356004717

Payments from drug & device makers

$6,782in general payments, 2019–2025

Across 404 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$856
  • Bayer$752
  • Xeris Pharmaceuticals, Inc.$541
  • Novo Nordisk$432
  • Dexcom, Inc.$409
  • Recordati_rare_diseases_inc.$301
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,782100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,782 in reported general payments places this provider in the 90th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$21,092
Medicare patients
107
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide208$297,812
MounjaroTirzepatide147$180,761
FarxigaDapagliflozin Propanediol53$70,326
JardianceEmpagliflozin55$69,053
TrulicityDulaglutide37$54,096
RybelsusSemaglutide20$25,106
Tresiba Flextouch U-200Insulin Degludec26$25,047
Fiasp FlextouchInsulin Aspart (Niacinamide)28$23,098
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$15,006
KerendiaFinerenone12$13,975
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$10,845
VascepaIcosapent Ethyl13$6,986
Humalog Kwikpen U-100Insulin Lispro17$4,753
Novolog FlexpenInsulin Aspart20$4,491
SynthroidLevothyroxine Sodium77$4,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$432$322,918228 claims
Lilly USA, LLCMounjaro, Trulicity$236$234,857184 claims
AstraZenecaFarxiga$219$70,32653 claims
Boehringer IngelheimJardiance$17$69,05355 claims
BayerKerendia$752$13,97512 claims
AbbVieSynthroid$282$4,15077 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →